Wall Street's open for biotech business, and Europe is taking notice

Wall Street's recent fervor over biotech companies has hardly been limited to local players, and the allure of handsome valuations and easy access to capital has brought more and more European drug developers across the Atlantic with hopes of becoming the next big thing in a boom market. As The Wall Street Journal notes, emerging biotechs the world over find the U.S. climate favorable to markets around the globe, a fact due in large part to the JOBS Act, which loosens the requirements for small companies seeking to go public. As a result, the likes of Galapagos ($GLPG), Cellectis ($CLLS) and Adaptimmune ($ADAP) have B-lined for the Nasdaq over the past few months, raising more than $400 million in the process. Story (sub. req.)

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.